Background Experimental animal data show that protection against severe acute respiratory
syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is …

Passive therapy with neutralizing human monoclonal antibodies (mAbs) could be an
effective therapy against severe acute respiratory syndrome coronavirus (SARS-CoV) …

Immune sera from convalescent patients have been shown to be effective in the treatment of
patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making …

Neutralizing antibody responses to the surface glycoproteins of enveloped viruses play an
important role in immunity. Many of these glycoproteins, including the severe acute …

Background. Severe acute respiratory syndrome (SARS) remains a significant public health
concern after the epidemic in 2003. Human monoclonal antibodies (MAbs) that neutralize …

The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide
epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an …

Background. Severe acute respiratory syndrome (SARS) emerged as a human disease in
2002. Detailed phylogenetic analysis and epidemiologic studies have suggested that the …

Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed
phylogenetic and epidemiological analyses have suggested that it originated from animals …

Background Immunotherapy with monoclonal antibodies (MAbs) offers safe interventions for
the prevention of infection in patients after organ transplantation and for the treatment of …

SUMMARY The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS‐
CoV) led to a rapid response not only to contain the outbreak but also to identify possible …